MX394291B - Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. - Google Patents

Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.

Info

Publication number
MX394291B
MX394291B MX2021009652A MX2021009652A MX394291B MX 394291 B MX394291 B MX 394291B MX 2021009652 A MX2021009652 A MX 2021009652A MX 2021009652 A MX2021009652 A MX 2021009652A MX 394291 B MX394291 B MX 394291B
Authority
MX
Mexico
Prior art keywords
nicotinamide riboside
treatment
compositions
skin conditions
skin
Prior art date
Application number
MX2021009652A
Other languages
English (en)
Spanish (es)
Other versions
MX2021009652A (es
Inventor
Ann Deren-Lewis
Troy Rhonemus
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of MX2021009652A publication Critical patent/MX2021009652A/es
Publication of MX394291B publication Critical patent/MX394291B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Cosmetics (AREA)
MX2021009652A 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel. MX394291B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361897713P 2013-10-30 2013-10-30
PCT/US2014/063260 WO2015066382A1 (en) 2013-10-30 2014-10-30 Nicotinamide riboside compositions for topical use in treating skin conditions

Publications (2)

Publication Number Publication Date
MX2021009652A MX2021009652A (es) 2022-07-26
MX394291B true MX394291B (es) 2025-03-24

Family

ID=53005146

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021009652A MX394291B (es) 2013-10-30 2014-10-30 Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
MX2016005574A MX385305B (es) 2013-10-30 2014-10-30 Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016005574A MX385305B (es) 2013-10-30 2014-10-30 Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.

Country Status (12)

Country Link
US (2) US10688118B2 (cg-RX-API-DMAC7.html)
EP (1) EP3063163B1 (cg-RX-API-DMAC7.html)
JP (1) JP6509844B2 (cg-RX-API-DMAC7.html)
KR (3) KR20160067195A (cg-RX-API-DMAC7.html)
CN (2) CN105873937A (cg-RX-API-DMAC7.html)
AU (1) AU2014342185B2 (cg-RX-API-DMAC7.html)
CA (1) CA2928656C (cg-RX-API-DMAC7.html)
ES (1) ES2925879T3 (cg-RX-API-DMAC7.html)
MX (2) MX394291B (cg-RX-API-DMAC7.html)
NZ (1) NZ719328A (cg-RX-API-DMAC7.html)
WO (1) WO2015066382A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201603314B (cg-RX-API-DMAC7.html)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10316054B2 (en) 2014-06-02 2019-06-11 Glaxosmithkline Intellectual Property (No. 2) Limited Preparation and use of crystalline beta-D-nicotinamide riboside
JP6559713B2 (ja) 2014-06-06 2019-08-14 グラクソスミスクライン、インテレクチュアル、プロパティー、（ナンバー２）、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ （Ｎｏ．２） Ｌｉｍｉｔｅｄ ニコチンアミドリボシド類似体ならびにその医薬組成物および使用
CN106715454B (zh) 2014-07-24 2020-06-16 格雷斯公司 烟酰胺核苷的结晶形式
FI3268379T3 (fi) 2015-03-09 2023-12-15 Grace W R & Co Nikotiiniamidiribosidin kiteinen muoto
BR112017019696A2 (pt) * 2015-03-16 2018-09-04 ChromaDex Inc. composto e usos de um composto
JP2018515485A (ja) 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー 皮膚の外観を改善する方法及びニコチンアミドリボシドを使用したそのための組成物
JP2018515486A (ja) 2015-05-01 2018-06-14 ザ プロクター アンド ギャンブル カンパニー ニコチンアミドリボシドを用いた皮膚外観の改善方法及びそのための組成物
JP6611099B2 (ja) * 2015-05-01 2019-11-27 ザ プロクター アンド ギャンブル カンパニー 皮膚の健康を改善する方法及びそのための組成物
AU2016274126A1 (en) * 2015-06-10 2018-01-18 Elysium Health, Inc. Nicotinamide riboside and pterostilbene compositions and methods for treatment of skin disorders
US20180177703A1 (en) * 2015-06-25 2018-06-28 N.V. Perricone Llc Niacinamide Mononucleotide Formulations For Skin Aging
US20160374908A1 (en) 2015-06-29 2016-12-29 The Procter & Gamble Company Skin care composition and methods of using the same
WO2017004102A1 (en) 2015-06-29 2017-01-05 The Procter & Gamble Company Multi-component skin care product comprising nicoinamide riboside in a multi-chambered container
US20160374918A1 (en) * 2015-06-29 2016-12-29 The Procter & Gamble Company Encapsulated skin care agent
MX380159B (es) 2016-01-11 2025-03-12 Procter & Gamble Metodo para tratar una afeccion cutanea y composiciones de este.
AU2017232930B2 (en) 2016-03-16 2021-03-25 ChromaDex Inc. B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
NZ747693A (en) * 2016-04-20 2023-07-28 Chromadex Inc Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors
CN109982706A (zh) * 2016-08-22 2019-07-05 益力舒健康公司 用于治疗神经退行性病症的烟酰胺核苷和紫檀芪的组合物和方法
WO2018089830A1 (en) 2016-11-11 2018-05-17 The Queen's University Of Belfast Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof
BR112019010607B1 (pt) 2016-11-29 2023-10-31 University Of Iowa Research Foundation Uso de precursores de nad e composição compreendendo os referidos precursores
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
WO2018113634A1 (en) 2016-12-21 2018-06-28 Unilever Plc Personal care compositions with glutathione precursor comprising 4-substituted resorcinols and amino acids
US11077039B2 (en) 2016-12-21 2021-08-03 Conopco, Inc. Topical skin lightening additive and composition with amino acids and nicotinamide compounds
EA201991003A1 (ru) 2016-12-21 2019-12-30 Юнилевер Н.В. Композиции для личной гигиены, содержащие малорастворимые соединения
US11337908B2 (en) 2016-12-21 2022-05-24 Conopco, Inc. Personal care compositions with cystine
RU2651047C1 (ru) * 2017-05-04 2018-04-18 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственная композиция цитопротекторного действия и способ ее получения
CN111093676A (zh) * 2017-05-18 2020-05-01 益力舒健康公司 改善睡眠的方法和组合物
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
EP3641725A1 (en) 2017-06-23 2020-04-29 The Procter and Gamble Company Composition and method for improving the appearance of skin
US11364187B2 (en) * 2017-07-28 2022-06-21 Centers For Age Control, Inc. Compositions and methods for preventing and reversing aspects of aging
US11219590B2 (en) * 2017-09-14 2022-01-11 Megumi Tanaka Anti-aging agent and anti-aging method
GB201716391D0 (en) * 2017-10-06 2017-11-22 Xobaderm Ltd Kit for delivery of an active compound into a biological barrier
US11414407B2 (en) 2017-12-22 2022-08-16 Elysium Health, Inc. Crystalline forms of nicotinamide riboside chloride
US11622963B2 (en) 2018-07-03 2023-04-11 The Procter & Gamble Company Method of treating a skin condition
US11052100B2 (en) * 2018-08-17 2021-07-06 Bontac Bio-Engineering (Shenzhen) Co., Ltd Stable nicotinamide riboside composition and preparation method thereof
KR102060374B1 (ko) * 2018-12-14 2019-12-30 주식회사 휴메딕스 지방알코올 컨쥬게이션된 니코틴아미드 리보사이드 유도체
US11833167B2 (en) 2018-12-17 2023-12-05 Mitopower Llc Nicotinyl riboside compounds and their uses
CA3148300A1 (en) * 2019-07-19 2021-01-28 Biosynth Ag Method of making nicotinamide ribofuranoside salts, nicotinamide ribofuranoside salts as such, and uses thereof
CN110638827A (zh) * 2019-10-17 2020-01-03 泓博元生命科技（深圳）有限公司 Nadh及其盐在制备皮肤色素抑制剂中的应用
CN111166760A (zh) * 2019-12-17 2020-05-19 浙江安赛新材料科技有限公司 β-烟酰胺单核苷酸或其前体的组合物及制备方法、应用
KR102315139B1 (ko) 2019-12-17 2021-10-20 주식회사 휴메딕스 지방아민 컨쥬게이션된 니코틴아미드 리보사이드 유도체
CN111184732B (zh) * 2020-03-04 2023-09-08 武汉华纳联合药业有限公司 一种复合组合物制剂及其制备方法和皮肤炎症中的应用
CN111454311B (zh) 2020-04-03 2021-10-19 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其组合物与制备方法
FR3110410A1 (fr) * 2020-05-20 2021-11-26 Nuvamid Sa Compositions cosmétiques anti-âge comprenant de la NMN
EP4153323A1 (fr) * 2020-05-20 2023-03-29 Nuvamid SA Compositions cosmetiques anti-age comprenant du nmn
US10959933B1 (en) 2020-06-01 2021-03-30 The Procter & Gamble Company Low pH skin care composition and methods of using the same
EP4157206A1 (en) 2020-06-01 2023-04-05 The Procter & Gamble Company Method of improving penetration of a vitamin b3 compound into skin
CN111632049A (zh) * 2020-06-09 2020-09-08 西北农林科技大学 一种通过综合矫正细胞活性氧簇代谢紊乱以缓解睾丸衰老损伤的复合配方
WO2022047182A1 (en) * 2020-08-28 2022-03-03 University Of Washington High dose nicotinamide adenine dinucleotide (nad) precursor regimens for reduction of inflammation in human patients with preexisting inflammation
US20240059727A1 (en) * 2021-01-19 2024-02-22 Biosynth Ag Method of making nicotinamide ribofuranoside salts by salt metathesis, the crystalline form of its tosylate salt and the co-crystallized form of its chloride:iodide salt
US12150461B2 (en) * 2021-05-04 2024-11-26 Sovida Solutions Ltd. Nicotinamide adenine dinucleotide (NAD) compositions, methods of manufacturing thereof, and methods of use thereof
CN114129509B (zh) * 2021-12-03 2023-12-01 药酚享科技(北京)有限公司 一种保湿性nmn亲水凝胶剂及其制备方法
CN116621898A (zh) * 2022-04-13 2023-08-22 深圳市迪克曼科技开发有限公司 烟酰胺核糖的有机酸盐及其结晶形态、制备方法与用途
KR102784901B1 (ko) * 2022-06-23 2025-03-21 제너럴바이오(주) Nr, nmn 및 nad를 함유한 피부 주름 개선용 화장료 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200305174B (en) * 2001-02-22 2004-09-23 Unilever Plc Skin composition for reducing skin oils and grease.
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1723227A4 (en) 2004-02-10 2007-09-19 Dartmouth College NICOTINAMIDRIBOSIDE KINASE COMPOSITIONS AND METHOD FOR THEIR USE
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
US20060229265A1 (en) 2005-03-30 2006-10-12 Sirtris Pharmaceuticals, Inc. Nicotinamide riboside and analogues thereof
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
WO2007008548A2 (en) * 2005-07-07 2007-01-18 Sirtris Pharmaceuticals, Inc. Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders
CN101257897A (zh) * 2005-07-07 2008-09-03 西特里斯药业公司 用于治疗或预防肥胖、胰岛素抵抗障碍和线粒体相关障碍的方法和相关组合物
EP3369738B1 (en) 2005-11-18 2020-05-20 Cornell Research Foundation, Inc. Method for making nicotinoyl ribosides and nicotinamide beta-riboside
JP2010520897A (ja) * 2007-03-12 2010-06-17 ディーエスエム アイピー アセッツ ビー．ブイ． 化粧品組成物
US20090069444A1 (en) 2007-09-07 2009-03-12 The United States Of America, As Represented By Th E Secretary Of Agriculture Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
KR101807328B1 (ko) * 2010-01-06 2017-12-08 가부시키가이샤 야쿠르트 혼샤 경구용 ｄｎａ 손상 수복 촉진제 및 엘라스타아제 활성 억제제

Also Published As

Publication number Publication date
MX2021009652A (es) 2022-07-26
MX385305B (es) 2025-03-18
US20200289536A1 (en) 2020-09-17
CA2928656C (en) 2020-07-28
KR20220098049A (ko) 2022-07-08
KR20210107895A (ko) 2021-09-01
US20160250241A1 (en) 2016-09-01
CN109985056A (zh) 2019-07-09
ES2925879T3 (es) 2022-10-20
NZ719328A (en) 2022-04-29
KR20160067195A (ko) 2016-06-13
ZA201603314B (en) 2017-09-27
WO2015066382A1 (en) 2015-05-07
CN105873937A (zh) 2016-08-17
JP6509844B2 (ja) 2019-05-08
EP3063163A1 (en) 2016-09-07
JP2016538271A (ja) 2016-12-08
MX2016005574A (es) 2016-12-09
EP3063163A4 (en) 2017-05-10
CA2928656A1 (en) 2015-05-07
EP3063163B1 (en) 2022-08-10
US10688118B2 (en) 2020-06-23
US11033568B2 (en) 2021-06-15
AU2014342185B2 (en) 2019-01-03

Similar Documents

Publication Publication Date Title
MX385305B (es) Composiciones de ribósido de nicotinamida para uso tópico en el tratamiento de afecciones de la piel.
BR112017019696A2 (pt) composto e usos de um composto
BR112014006455A2 (pt) alquilamidotiazóis, preparações cosméticas ou dermatológicas com um teor de um ou vários alquilamidotiazóis e uso de um ou vários alquilamidotiazóis
EA201890435A1 (ru) Производные никотинамидмононуклеотида и их применение
PE20150223A1 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciacion y usos de los mismos
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
CL2016000544A1 (es) Composición cosmética que comprende 0,0001 a 10% en peso de extracto de guacatonga (casearia sylvestris) y 0,00005 a 10% en peso de extracto de aroeira (schinus terebinthifolius raddi) ambos respecto al peso total de la composición; uso de la composición en la prevención y/o tratamiento de los signos de envejicimiento de la piel; metodo para prevenir y/o tratar los signos de envejecimiento de la piel.
ES2572211T3 (es) Regeneración de músculo esquelético utilizando células madre mesenquimales
BR112015007878A2 (pt) composto compreendendo oligonucleotídeo modificado, composição, combinação e uso dos mesmos
BR112015022514A2 (pt) composições que compreendem selênio e uso das mesmas para o tratamento e prevenção de doença ou condições associadas à disfunção mitocondrial
BRPI1106572B8 (pt) Composições que compreendem um retinoide e um inibidor de nfkb e seus métodos de uso
BRPI0919020B8 (pt) uso de células de linhagem monocitária enriquecidas para tratar isquemia e para tratar angina pectoris
BR112015006790A2 (pt) composição de cetoprofeno tópico
BR112016000350A8 (pt) métodos de tratamento de lesões inflamatórias da rosácea e usos de uma composição farmacêutica
RU2014150505A (ru) Способ идентификации лигандов рецептора ahr, которые обладают терапевтической себосупрессивной активностью, и указанные лиганды
BR112014003071A2 (pt) tratamento de doença vascular periférica com o uso de células derivadas do tecido do cordão umbilical
WO2012116990A3 (en) Novel use
CO6660486A2 (es) Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea
MX385999B (es) Composiciones y métodos para tratamiento de la piel.
BR112012015984A2 (pt) composição para melhorar a função cerebral, e, polipeptídeo
MX349854B (es) Composiciones antitranspirantes y metodo para reducir la transpiracion.
BR112015002041A2 (pt) formulação transdérmica contendo inibidores de cox
UY34009A (es) ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?.
AR097216A1 (es) Composición para el tratamiento contra el envejecimiento de la piel
CR20130488A (es) Derivados de tieno [2,3-d]pirimidina y su uso para tratar arritmia